Ibogaine for Depression,
OCD & Traumatic Brain Injury

The analytics dashboard below draws live values from the clinical records system across four validated scales, PHQ-9 (depression), GAD-7 (anxiety), Y-BOCS (OCD), and a composite TBI cognitive recovery score, and renders only when the cohort holds real assessment data. These three conditions are rarely grouped in the same study, but their inclusion here is methodologically deliberate: depression, OCD, and TBI all involve pathological rigidity in neural circuit function, and tracking their responses to a shared neuroplasticity-based intervention reveals whether the therapeutic mechanism is condition-specific or operates at a more fundamental neurobiological level.

Ibogaine's BDNF and GDNF upregulation, sigma-1 receptor agonism, and temporary disruption of pathological default mode network activity create a window of enhanced neural flexibility that operates across this entire diagnostic spectrum. In depression, this disrupts self-referential rumination loops anchored in the default mode network. In OCD, it interrupts the cortico-striato-thalamo-cortical hyperdrive that sustains compulsive cycles. In TBI, it modulates post-concussive neuroinflammation and promotes axonal repair processes. The dashboard captures whether these parallel mechanisms produce measurable improvement in the same patient population within the same treatment window.

The 3 to 7 days following ibogaine administration is the window in which BDNF upregulation and default mode network reorganization are most active, which is why depression, OCD, and cognitive recovery are all scored across it rather than only at discharge. If the therapeutic mechanism is not condition-specific but operates at the level of fundamental neural circuit plasticity, three clinically distinct conditions should move inside the same pharmacological window. That is the prediction the protocol is built to test, and the instruments are scheduled to catch it either way.

Comorbid presentation is where the mechanism gets its most interesting test. The neuroinflammatory burden in TBI plausibly amplifies depressive and obsessive-compulsive circuitry dysfunction independently, so ibogaine's anti-neuroinflammatory properties would be addressing a compounding effect rather than three separate diseases. Resolving a TBI-driven neuroinflammatory cascade would then be expected to assist the depression and OCD response rather than compete with it, which is why guests carrying more than one diagnosis are scored on every relevant instrument rather than only their primary one.

Depression and anxiety are scored on two of psychiatry's most widely validated self-report instruments, and the bands matter as much as the numbers. The PHQ-9 (Patient Health Questionnaire-9) measures depression severity on a 0 to 27 scale: scores of 15 and above indicate moderately severe depression, while scores of 20 or above indicate severe depression. The GAD-7 (Generalized Anxiety Disorder 7-item scale) measures anxiety severity from 0 to 21, with scores above 15 indicating severe anxiety. Guests accepted into this protocol sit in the upper bands of both, which is the point: this is not a population that responds to any intervention.

Severe depression and severe anxiety co-occurring is clinically typical rather than unusual, because the anxious rumination the GAD-7 captures frequently accompanies and amplifies treatment-resistant depressive disorder. Ibogaine's simultaneous action on both the serotonergic and default mode network pathways driving these presentations makes it a particularly rational intervention for comorbid depression-anxiety, a profile that often requires multiple medications and years of therapy under conventional approaches.

The PHQ-9 and the GAD-7 cover the affective and ruminative dimensions of neuropsychiatric dysfunction, the subjective suffering layer. They tell only part of the neuroplasticity story. The Y-BOCS and the TBI cognitive composite cover the structural and behavioral dimensions instead: circuit-level disruptions that standard antidepressants and anxiolytics do not address, and the place where ibogaine's circuit-remodeling effects would either penetrate the deeper dysfunction underlying obsessive-compulsive and post-concussive presentations or fail to.

The mechanism that would connect depression and anxiety improvement to OCD and TBI recovery is not coincidental: it is the shared neuroplasticity pathway. Once BDNF upregulation and default mode network reorganization open a window of neural flexibility, the same biological conditions that permit affective circuit reconfiguration are simultaneously available to the cortico-striato-thalamo-cortical loops in OCD and the axonal repair processes in TBI. This is why multi-condition improvement within a single treatment window is not only possible but mechanistically expected.

Taken together, the four-metric profile is designed to answer a single question about ibogaine's breadth of action: does one intervention move a guest across clinically meaningful thresholds on instruments that measure different kinds of dysfunction. On the PHQ-9 that threshold is the step down out of the severe band, something most pharmacological interventions reach only after months of titration. On the Y-BOCS it is the step out of the severe range, where the subjective experience of obsessional intrusion and compulsive drive is meaningfully reduced rather than merely dulled.

The TBI cognitive composite is the measure we watch most closely, because no currently approved treatment produces meaningful cognitive recovery in this population. Standard TBI rehabilitation focuses on compensatory strategies and symptom management, whereas ibogaine is proposed to operate at the level of neural substrate repair through anti-neuroinflammatory and neurotrophic mechanisms that address the underlying injury pathophysiology. Convergent movement across all four metrics inside a single 14-day protocol would be the strongest available evidence for a fundamental neuroplasticity mechanism rather than any condition-specific pharmacological action, which is exactly why we will not publish a figure for it until a cohort of at least 20 people holds paired data. When one does, it goes up at mindscaperetreat.com/outcomes.